Your browser is no longer supported. Please, upgrade your browser.
Xencor, Inc.
Index- P/E- EPS (ttm)-1.45 Insider Own0.20% Shs Outstand57.27M Perf Week-6.65%
Market Cap2.64B Forward P/E- EPS next Y-1.98 Insider Trans-3.24% Shs Float56.29M Perf Month-3.88%
Income-82.60M PEG- EPS next Q-0.38 Inst Own- Short Float5.32% Perf Quarter14.33%
Sales84.40M P/S31.27 EPS this Y135.20% Inst Trans0.05% Short Ratio11.52 Perf Half Y30.94%
Book/sh9.93 P/B4.71 EPS next Y-40.40% ROA-12.60% Target Price51.00 Perf Year40.21%
Cash/sh9.77 P/C4.79 EPS next 5Y- ROE-14.20% 52W Range19.35 - 58.35 Perf YTD7.17%
Dividend- P/FCF- EPS past 5Y23.50% ROI2.30% 52W High-19.86% Beta0.80
Dividend %- Quick Ratio8.10 Sales past 5Y75.10% Gross Margin- 52W Low141.65% ATR3.00
Employees166 Current Ratio8.10 Sales Q/Q62.40% Oper. Margin- RSI (14)41.96 Volatility8.78% 5.75%
OptionableYes Debt/Eq0.00 EPS Q/Q-21.40% Profit Margin-97.90% Rel Volume0.86 Prev Close48.50
ShortableYes LT Debt/Eq0.00 EarningsFeb 23 AMC Payout- Avg Volume259.82K Price46.76
Recom1.80 SMA20-6.36% SMA50-2.59% SMA20020.49% Volume223,111 Change-3.59%
Feb-24-21Upgrade Raymond James Mkt Perform → Outperform $58
Mar-04-20Initiated Barclays Underweight $28
Feb-25-20Upgrade Guggenheim Neutral → Buy $43
Jan-30-20Initiated RBC Capital Mkts Outperform $44
Nov-20-19Resumed Guggenheim Neutral
Aug-07-19Downgrade Raymond James Outperform → Mkt Perform
Aug-07-19Downgrade Guggenheim Buy → Neutral
Jun-13-19Initiated Mizuho Buy
Apr-12-19Initiated Guggenheim Buy
Mar-27-19Initiated Berenberg Buy $45
Mar-15-19Initiated Raymond James Outperform
Sep-10-18Resumed BTIG Research Buy $56
Mar-28-18Resumed Leerink Partners Outperform $36
Mar-02-17Reiterated Wedbush Outperform $27 → $33
Mar-02-17Initiated Instinet Neutral $21
Oct-04-16Initiated Piper Jaffray Overweight
Dec-22-15Initiated Canaccord Genuity Buy $20
Aug-05-15Reiterated MLV & Co Buy $22 → $29
Feb-12-15Reiterated Oppenheimer Outperform $22 → $28
Jan-28-15Reiterated MLV & Co Buy $18 → $22
Feb-25-21 08:08AM  
Feb-24-21 12:01AM  
Feb-23-21 04:22PM  
Feb-16-21 04:01PM  
Feb-12-21 08:28AM  
Feb-04-21 04:01PM  
Jan-07-21 08:45AM  
Jan-06-21 04:01PM  
Dec-16-20 10:21PM  
Dec-07-20 08:01AM  
Dec-06-20 05:00PM  
Nov-12-20 04:01PM  
Nov-11-20 04:02PM  
Nov-10-20 07:51AM  
Nov-09-20 08:00AM  
Nov-06-20 03:30PM  
Nov-05-20 05:45PM  
Nov-04-20 10:15AM  
Oct-29-20 04:01PM  
Oct-14-20 05:00PM  
Oct-13-20 12:03PM  
Oct-02-20 09:00AM  
Sep-23-20 12:09PM  
Sep-09-20 04:01PM  
Sep-03-20 08:01AM  
Aug-05-20 04:01PM  
Aug-04-20 05:25PM  
Jul-31-20 10:49PM  
Jul-28-20 05:01PM  
Jul-14-20 11:14AM  
Jul-08-20 08:01AM  
Jun-30-20 11:35PM  
Jun-22-20 09:06AM  
Jun-08-20 01:48PM  
May-26-20 04:01PM  
May-15-20 12:01AM  
May-13-20 05:00PM  
May-11-20 01:35PM  
May-08-20 09:30PM  
May-07-20 04:01PM  
Apr-30-20 04:01PM  
Apr-13-20 03:49PM  
Apr-07-20 02:10PM  
Mar-26-20 08:23AM  
Mar-25-20 04:01PM  
Mar-02-20 02:55PM  
Feb-28-20 07:43AM  
Feb-26-20 11:59AM  
Feb-24-20 05:45PM  
Feb-18-20 08:01AM  
Feb-17-20 12:30PM  
Feb-06-20 04:01PM  
Feb-05-20 10:28AM  
Jan-09-20 05:10PM  
Jan-08-20 12:08PM  
Dec-30-19 10:13AM  
Dec-20-19 08:01AM  
Dec-18-19 08:01AM  
Dec-14-19 08:05PM  
Dec-09-19 10:00AM  
Nov-19-19 12:58PM  
Nov-18-19 11:48PM  
Nov-13-19 04:01PM  
Nov-06-19 09:00AM  
Nov-05-19 06:05PM  
Oct-29-19 04:01PM  
Oct-28-19 10:31AM  
Oct-21-19 12:55PM  
Oct-10-19 03:34PM  
Sep-26-19 04:01PM  
Sep-10-19 04:01PM  
Aug-23-19 10:00AM  
Aug-22-19 09:15PM  
Aug-21-19 06:53AM  
Aug-08-19 11:13AM  
Aug-06-19 06:05PM  
Aug-01-19 04:01PM  
Jul-30-19 04:01PM  
Jul-12-19 06:16PM  
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases. It develops its antibody product candidates to treat cancer and autoimmune diseases. The company's product candidates include XmAb5871, an immune inhibitor, which has been completed Phase II clinical trial for the treatment of autoimmune diseases; AIMab7195, which is in development and commercialization stage. Its product candidates also comprise XmAb14045, a bispecific antibody which is in Phase I clinical trial for the treatment of acute myeloid leukemia; plamotamab (XmAb13676) that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers Tafasitamab, an antibody drug candidate for the treatment of patients with relapsed/refractory diffuse; AMG424, a bispecific antibody that targets CD38 and CD3, which is in Phase I clinical trial for the treatment of various myeloma; and AMG509, a bispecific antibody that is in preclinical development stage to treat prostate cancer. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, and XmAb23104 which are in preclinical Phase. Additionally, it offers XmAb24306, initial cytokine candidate which is in Phase I clinical trial. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc.; Amgen Inc.; Catalent Pharma Solutions LLC.; Janssen Biotech, Inc.; MorphoSys AG; Incyte Corporation; and The University of Texas MD Anderson Cancer Center. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Yang AllenSR. VICE PRESIDENT & CMODec 17Sale43.853,777165,62128,395Dec 18 12:19 PM
Kuch John JSr. Vice President & CFOJun 12Option Exercise11.0510,000110,50090,602Jun 16 08:45 PM
STAFFORD JOHN S III10% OwnerApr 06Sale27.43644,77117,685,509606,005Apr 08 04:26 PM
Ronin Capital, LLC10% OwnerMar 20Sale29.8950,7701,517,6425,012,430Mar 23 05:37 PM
Ronin Capital, LLC10% OwnerMar 19Sale28.2326,800756,5935,063,200Mar 23 05:37 PM